Medical Properties Trust, Inc. Reports Fourth Quarter and Full-Year Results
Medical Properties Trust (MPW) reported its Q4 and full-year 2024 results, highlighting significant financial developments. The company completed approximately $5.5 billion in asset monetization transactions, including a February $2.5 billion senior secured notes offering with a 7.885% blended coupon rate, addressing all debt maturities through 2026.
Q4 2024 showed a net loss of ($0.69) per share and Normalized FFO of $0.18 per share, while full-year 2024 reported a net loss of ($4.02) per share and NFFO of $0.80. The quarter's results include about $415 million in impairments related to Prospect Medical Group and PHP Holdings.
The company's portfolio comprises 396 properties with approximately 39,000 licensed beds across nine countries, with total assets of $14.3 billion. MPW declared a quarterly dividend of $0.08 per share in February.
Medical Properties Trust (MPW) ha riportato i risultati del quarto trimestre e dell'intero anno 2024, evidenziando sviluppi finanziari significativi. L'azienda ha completato circa 5,5 miliardi di dollari in transazioni di monetizzazione degli asset, inclusa un'offerta di 2,5 miliardi di dollari in note senior garantite a febbraio, con un tasso di interesse misto del 7,885%, coprendo tutte le scadenze del debito fino al 2026.
Il quarto trimestre del 2024 ha mostrato una perdita netta di ($0,69) per azione e un FFO normalizzato di $0,18 per azione, mentre l'intero anno 2024 ha riportato una perdita netta di ($4,02) per azione e un NFFO di $0,80. I risultati del trimestre includono circa 415 milioni di dollari in svalutazioni legate a Prospect Medical Group e PHP Holdings.
Il portafoglio dell'azienda comprende 396 proprietà con circa 39.000 letti autorizzati in nove paesi, con attivi totali di 14,3 miliardi di dollari. MPW ha dichiarato un dividendo trimestrale di $0,08 per azione a febbraio.
Medical Properties Trust (MPW) informó sus resultados del cuarto trimestre y del año completo 2024, destacando desarrollos financieros significativos. La compañía completó aproximadamente 5.5 mil millones de dólares en transacciones de monetización de activos, incluida una oferta de 2.5 mil millones de dólares en notas senior garantizadas en febrero, con una tasa de cupón mezclada del 7.885%, abordando todos los vencimientos de deuda hasta 2026.
El cuarto trimestre de 2024 mostró una pérdida neta de ($0.69) por acción y un FFO normalizado de $0.18 por acción, mientras que el año completo 2024 reportó una pérdida neta de ($4.02) por acción y un NFFO de $0.80. Los resultados del trimestre incluyen aproximadamente 415 millones de dólares en deterioros relacionados con Prospect Medical Group y PHP Holdings.
El portafolio de la compañía comprende 396 propiedades con aproximadamente 39,000 camas autorizadas en nueve países, con activos totales de 14.3 mil millones de dólares. MPW declaró un dividendo trimestral de $0.08 por acción en febrero.
메디컬 프로퍼티스 트러스트 (MPW)는 2024년 4분기 및 연간 실적을 보고하며 중요한 재무 발전을 강조했습니다. 이 회사는 약 55억 달러의 자산 수익화 거래를 완료했으며, 2월에는 25억 달러의 선순위 담보 노트 발행을 포함하여 7.885%의 혼합 쿠폰 금리를 적용하여 2026년까지 모든 부채 만기를 해결했습니다.
2024년 4분기는 주당 순손실이 ($0.69)였고, 정상화된 FFO는 주당 $0.18이었으며, 2024년 전체 연간 실적은 주당 순손실이 ($4.02)였고 NFFO는 $0.80이었습니다. 분기의 결과에는 Prospect Medical Group 및 PHP Holdings와 관련된 약 4억 1500만 달러의 자산 손상이 포함되어 있습니다.
회사의 포트폴리오는 396개 자산과 약 39,000개의 면허 침대를 포함하여 아홉 개 국가에 걸쳐 있으며, 총 자산은 143억 달러입니다. MPW는 2월에 주당 $0.08의 분기 배당금을 선언했습니다.
Medical Properties Trust (MPW) a publié ses résultats du quatrième trimestre et de l'année 2024, mettant en évidence des développements financiers significatifs. L'entreprise a réalisé environ 5,5 milliards de dollars en transactions de monétisation d'actifs, y compris une offre de 2,5 milliards de dollars en obligations sécurisées senior en février, avec un taux de coupon mixte de 7,885%, couvrant toutes les échéances de la dette jusqu'en 2026.
Le quatrième trimestre de 2024 a montré une perte nette de ($0,69) par action et un FFO normalisé de $0,18 par action, tandis que l'année entière 2024 a rapporté une perte nette de ($4,02) par action et un NFFO de $0,80. Les résultats du trimestre incluent environ 415 millions de dollars en amortissements liés à Prospect Medical Group et PHP Holdings.
Le portefeuille de l'entreprise comprend 396 propriétés avec environ 39 000 lits autorisés dans neuf pays, avec des actifs totaux de 14,3 milliards de dollars. MPW a déclaré un dividende trimestriel de $0,08 par action en février.
Medical Properties Trust (MPW) hat seine Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 veröffentlicht und dabei bedeutende finanzielle Entwicklungen hervorgehoben. Das Unternehmen hat etwa 5,5 Milliarden Dollar an Vermögensmonetarisierungstransaktionen abgeschlossen, einschließlich einer 2,5 Milliarden Dollar umfassenden Emission von vorrangigen gesicherten Anleihen im Februar, mit einem gemischten Kuponzins von 7,885%, um alle Fälligkeiten der Schulden bis 2026 zu adressieren.
Im vierten Quartal 2024 gab es einen Nettoverlust von ($0,69) pro Aktie und einen normalisierten FFO von $0,18 pro Aktie, während für das gesamte Jahr 2024 ein Nettoverlust von ($4,02) pro Aktie und ein NFFO von $0,80 berichtet wurde. Die Ergebnisse des Quartals beinhalten etwa 415 Millionen Dollar an Wertminderungen in Verbindung mit der Prospect Medical Group und PHP Holdings.
Das Portfolio des Unternehmens umfasst 396 Immobilien mit etwa 39.000 lizenzierten Betten in neun Ländern, mit einem Gesamtvermögen von 14,3 Milliarden Dollar. MPW erklärte im Februar eine vierteljährliche Dividende von $0,08 pro Aktie.
- Secured $2.5B in senior notes, addressing debt maturities through 2026
- Amended credit line with $1.5B commitment extended to June 2027
- Portfolio remains attractive to investors (5.5x oversubscribed secured notes)
- Strong performance in European operations with growing occupancy
- Q4 net loss of $0.69 per share
- Full-year 2024 net loss of $4.02 per share
- $415M in impairments related to Prospect and PHP
- Prospect Medical Group bankruptcy filing
- Quarterly dividend reduced to $0.08 per share
Insights
MPT's Q4 results reveal a company in the midst of a significant financial restructuring while facing serious operational challenges. The $0.18 NFFO per share for Q4 represents a 50% decline from the $0.36 in Q4 2023, highlighting deteriorating cash flow fundamentals despite management's efforts to stabilize the business.
The headline achievement—a $2.5 billion senior secured notes offering at 7.885%—comes at a significant cost. This shift to secured debt (versus unsecured previously) with a high interest rate reflects lenders' demands for enhanced protection, effectively creating a tiered capital structure that subordinates existing unsecured creditors. While the 5.5x oversubscription indicates investor appetite, it's likely driven by yield-seeking behavior in a high-rate environment rather than confidence in MPT's underlying business.
The $415 million in impairments related to Prospect and PHP continues a troubling pattern of write-downs. Prospect's Chapter 11 filing and the subsequent settlement agreement will likely result in further value deterioration, as bankruptcy sales rarely maximize asset values. This settlement represents MPT's pragmatic approach to recovering whatever value remains rather than fighting a protracted legal battle.
MPT's aggressive asset monetization strategy—$5.5 billion in 2024—has successfully addressed near-term liquidity concerns but raises questions about long-term growth potential. The company is effectively shrinking to survive, which may eventually stabilize the business but at a significantly reduced scale and with growth prospects.
The $0.08 quarterly dividend represents an approximately 80% reduction from pre-crisis levels, reflecting severe financial strain. Even at this reduced level, the dividend payout ratio remains high relative to current NFFO, suggesting financial flexibility.
European portfolio performance appears to be a bright spot, particularly in the UK with Circle Health, but these positive trends are overshadowed by continued challenges with certain US operators. The transition of 15 hospitals to new operators in September shows early positive signs but remains in early stages of stabilization.
MPT has successfully bought time through 2026, but fundamental business challenges persist. The path to recovery will require continued operational improvements from tenants, successful resolution of troubled assets, and maintaining adequate liquidity while managing a higher interest burden.
Completed Approximately
-
Net loss of (
) and Normalized Funds from Operations (“NFFO”) of$0.69 for the 2024 fourth quarter and net loss of ($0.18 ) and NFFO of$4.02 for the full-year 2024, all on a per share basis. Fourth quarter 2024 net loss includes approximately$0.80 ($415 million per share) in impairments and fair market value adjustments related to Prospect Medical Group (“Prospect”) and PHP Holdings (“PHP”);$0.69 -
Completed a well-oversubscribed private offering of more than
of senior secured notes due in 2032 at a blended coupon rate of$2.5 billion 7.885% , the proceeds from which will repay all debt maturities until October 2026 and result in expected combined cash and line of credit availability of ;$1.4 billion -
Simultaneous to the senior secured notes offering, the Company amended its line of credit to share collateral with the new senior secured notes and received universal affirmation of the long-standing banking group’s approximate
commitment with a fully extended (at MPT’s option) maturity in June 2027;$1.5 billion -
Commenced rent during the fourth quarter on a
building improvement project in$50 million Idaho Falls, Idaho ; -
Sold two post-acute properties and agreed to sell an additional general acute facility during January for combined proceeds of approximately
; and$45 million -
Declared a regular quarterly dividend of
per share in February.$0.08
Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer, said, “We delivered on exactly what we said we would do in 2024 by using proceeds from transactions to accelerate repayment of debt maturities. Our global real estate portfolio remains attractive to sophisticated investors, as evidenced by our recent five-and-a-half times oversubscribed secured notes transaction. We improved the operator diversification of our portfolio and effectively addressed all debt maturities through 2026, positioning MPT to pursue a range of shareholder value initiatives in 2025.”
Included in the financial tables accompanying this press release is information about the Company’s assets and liabilities, operating results, and reconciliations of net (loss) income to NFFO, including per share amounts, all on a basis comparable to 2023 results.
PORTFOLIO UPDATE
Medical Properties Trust has total assets of approximately
Hospitals around
In
Following the first full quarter of operations since transitioning 15 hospitals to new operators in September, MPT is encouraged by performance trends being reported across this portfolio as well as by a fifth tenant who leased two additional facilities in November. Across this footprint, our tenants have reported improving volumes, increasing patient satisfaction, and stabilization of staffing and supplies.
In January, Prospect Medical Group commenced an in-court restructuring process under Chapter 11 of the
OPERATING RESULTS
Net loss for the fourth quarter and year ended December 31, 2024 was (
NFFO for the fourth quarter and year ended December 31, 2024 was
CONFERENCE CALL AND WEBCAST
The Company has scheduled a conference call and webcast for February 27, 2025 at 11:00 a.m. Eastern Time to present the Company’s financial and operating results for the quarter and year ended December 31, 2024. The dial-in numbers for the conference call are 877-883-0383 (
A telephone and webcast replay of the call will be available beginning shortly after the call’s completion. The telephone replay will be available through March 13, 2025, using dial-in numbers 877-344-7529 (
The Company’s supplemental information package for the current period will also be available on the Company’s website in the Investor Relations section.
The Company uses, and intends to continue to use, the Investor Relations page of its website, which can be found at www.medicalpropertiestrust.com, as a means of disclosing material nonpublic information and of complying with its disclosure obligations under Regulation FD, including, without limitation, through the posting of investor presentations that may include material nonpublic information. Accordingly, investors should monitor the Investor Relations page, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.
About Medical Properties Trust, Inc.
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “estimate”, “target”, “anticipate”, “believe”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding our strategies, objectives, asset sales and other liquidity transactions (including the use of proceeds thereof), expected re-tenanting of facilities and any related regulatory approvals, and expected outcomes from Prospect’s Chapter 11 restructuring process. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) the risk that the outcome and terms of the bankruptcy restructuring of Prospect will not be consistent with those anticipated by the Company; (ii) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (iii) the risk that previously announced or contemplated property sales, loan repayments, and other capital recycling transactions do not occur as anticipated or at all; (iv) the risk that MPT is not able to attain its leverage, liquidity and cost of capital objectives within a reasonable time period or at all; (v) MPT’s ability to obtain or modify the terms of debt financing on attractive terms or at all, as a result of changes in interest rates and other factors, which may adversely impact its ability to pay down, refinance, restructure or extend its indebtedness as it becomes due, or pursue acquisition and development opportunities; (vi) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us; (vii) the ability of our tenants and operators to operate profitably and generate positive cash flow, remain solvent, comply with applicable laws, rules and regulations in the operation of our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (viii) the risk that we are unable to monetize our investments in certain tenants at full value within a reasonable time period or at all; and (ix) the risks and uncertainties of litigation or other regulatory proceedings.
The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned “Risk Factors” in our Annual Report on Form 10-Ks and our Form 10-Qs, and as may be updated in our other filings with the SEC. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.
MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES | |||||||
Consolidated Balance Sheets | |||||||
(Amounts in thousands, except for per share data) | |||||||
December 31, 2024 | December 31, 2023 | ||||||
Assets | (Unaudited) | (A) | |||||
Real estate assets | |||||||
Land, buildings and improvements, intangible lease assets, and other | $ |
11,259,842 |
|
$ |
13,237,187 |
|
|
Investment in financing leases |
|
1,057,770 |
|
|
1,231,630 |
|
|
Real estate held for sale |
|
34,019 |
|
|
- |
|
|
Mortgage loans |
|
119,912 |
|
|
309,315 |
|
|
Gross investment in real estate assets |
|
12,471,543 |
|
|
14,778,132 |
|
|
Accumulated depreciation and amortization |
|
(1,422,948 |
) |
|
(1,407,971 |
) |
|
Net investment in real estate assets |
|
11,048,595 |
|
|
13,370,161 |
|
|
Cash and cash equivalents |
|
332,335 |
|
|
250,016 |
|
|
Interest and rent receivables |
|
36,327 |
|
|
45,059 |
|
|
Straight-line rent receivables |
|
700,783 |
|
|
635,987 |
|
|
Investments in unconsolidated real estate joint ventures |
|
1,156,397 |
|
|
1,474,455 |
|
|
Investments in unconsolidated operating entities |
|
439,578 |
|
|
1,778,640 |
|
|
Other loans |
|
109,175 |
|
|
292,615 |
|
|
Other assets |
|
471,404 |
|
|
457,911 |
|
|
Total Assets | $ |
14,294,594 |
|
$ |
18,304,844 |
|
|
Liabilities and Equity | |||||||
Liabilities | |||||||
Debt, net | $ |
8,848,112 |
|
$ |
10,064,236 |
|
|
Accounts payable and accrued expenses |
|
454,209 |
|
|
412,178 |
|
|
Deferred revenue |
|
29,445 |
|
|
37,962 |
|
|
Obligations to tenants and other lease liabilities |
|
129,045 |
|
|
156,603 |
|
|
Total Liabilities |
|
9,460,811 |
|
|
10,670,979 |
|
|
Equity | |||||||
Preferred stock, |
|||||||
outstanding |
|
- |
|
|
- |
|
|
Common stock, |
|||||||
outstanding - 600,403 shares at December 31, 2024 and 598,991 |
|
|
|
|
|||
shares at December 31, 2023 |
|
600 |
|
599 |
|||
Additional paid-in capital |
|
8,584,917 |
|
|
8,560,309 |
|
|
Retained deficit |
|
(3,658,516 |
) |
|
(971,809 |
) |
|
Accumulated other comprehensive (loss) income |
|
(94,272 |
) |
|
42,501 |
|
|
Total Medical Properties Trust, Inc. Stockholders' Equity |
|
4,832,729 |
|
|
7,631,600 |
|
|
Non-controlling interests |
|
1,054 |
|
|
2,265 |
|
|
Total Equity |
|
4,833,783 |
|
|
7,633,865 |
|
|
Total Liabilities and Equity | $ |
14,294,594 |
|
$ |
18,304,844 |
|
|
(A) Financials have been derived from the prior year audited financial statements. |
MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES | |||||||||||||||
Consolidated Statements of Income | |||||||||||||||
(Unaudited) | |||||||||||||||
(Amounts in thousands, except for per share data) | For the Three Months Ended | For the Twelve Months Ended | |||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | ||||||||||||
Revenues | |||||||||||||||
Rent billed | $ |
166,965 |
|
$ |
78,421 |
|
$ |
719,749 |
|
$ |
803,375 |
|
|||
Straight-line rent |
|
43,695 |
|
|
(166,769 |
) |
|
163,414 |
|
|
(127,894 |
) |
|||
Income from financing leases |
|
9,819 |
|
|
19,412 |
|
|
63,651 |
|
|
127,141 |
|
|||
Interest and other income |
|
11,365 |
|
|
(53,447 |
) |
|
48,733 |
|
|
69,177 |
|
|||
Total revenues |
|
231,844 |
|
|
(122,383 |
) |
|
995,547 |
|
|
871,799 |
|
|||
Expenses | |||||||||||||||
Interest |
|
101,466 |
|
|
102,338 |
|
|
417,824 |
|
|
411,171 |
|
|||
Real estate depreciation and amortization |
|
64,956 |
|
|
77,295 |
|
|
447,657 |
|
|
603,360 |
|
|||
Property-related (A) |
|
9,780 |
|
|
3,298 |
|
|
27,255 |
|
|
41,567 |
|
|||
General and administrative |
|
28,489 |
|
|
30,150 |
|
|
133,789 |
|
|
145,588 |
|
|||
Total expenses |
|
204,691 |
|
|
213,081 |
|
|
1,026,525 |
|
|
1,201,686 |
|
|||
Other (expense) income | |||||||||||||||
Gain (loss) on sale of real estate |
|
3,497 |
|
|
(2,024 |
) |
|
478,693 |
|
|
(1,815 |
) |
|||
Real estate and other impairment charges, net |
|
(386,973 |
) |
|
(283,619 |
) |
|
(1,825,402 |
) |
|
(376,907 |
) |
|||
Earnings (loss) from equity interests |
|
2,923 |
|
|
(20,873 |
) |
|
(366,642 |
) |
|
13,967 |
|
|||
Debt refinancing and unutilized financing (costs) benefit |
|
(615 |
) |
|
239 |
|
|
(4,292 |
) |
|
285 |
|
|||
Other (including fair value adjustments on securities) |
|
(48,744 |
) |
|
(17,861 |
) |
|
(615,565 |
) |
|
7,586 |
|
|||
Total other expense |
|
(429,912 |
) |
|
(324,138 |
) |
|
(2,333,208 |
) |
|
(356,884 |
) |
|||
Loss before income tax |
|
(402,759 |
) |
|
(659,602 |
) |
|
(2,364,186 |
) |
|
(686,771 |
) |
|||
Income tax (expense) benefit |
|
(9,563 |
) |
|
(3,982 |
) |
|
(44,101 |
) |
|
130,679 |
|
|||
Net loss |
|
(412,322 |
) |
|
(663,584 |
) |
|
(2,408,287 |
) |
|
(556,092 |
) |
|||
Net income attributable to non-controlling interests |
|
(526 |
) |
|
(359 |
) |
|
(1,984 |
) |
|
(384 |
) |
|||
Net loss attributable to MPT common stockholders | $ |
(412,848 |
) |
$ |
(663,943 |
) |
$ |
(2,410,271 |
) |
$ |
(556,476 |
) |
|||
Earnings per common share - basic and diluted: | |||||||||||||||
Net loss attributable to MPT common stockholders | $ |
(0.69 |
) |
$ |
(1.11 |
) |
$ |
(4.02 |
) |
$ |
(0.93 |
) |
|||
Weighted average shares outstanding - basic |
|
600,402 |
|
|
598,984 |
|
|
600,248 |
|
|
598,518 |
|
|||
Weighted average shares outstanding - diluted |
|
600,402 |
|
|
598,984 |
|
|
600,248 |
|
|
598,518 |
|
|||
Dividends declared per common share | $ |
0.08 |
|
$ |
0.15 |
|
$ |
0.46 |
|
$ |
0.88 |
|
|||
(A) Includes |
MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES | |||||||||||||||
Reconciliation of Net (Loss) Income to Funds From Operations | |||||||||||||||
(Unaudited) | |||||||||||||||
(Amounts in thousands, except for per share data) | For the Three Months Ended | For the Twelve Months Ended | |||||||||||||
December 31, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 | ||||||||||||
FFO information: | |||||||||||||||
Net loss attributable to MPT common stockholders | $ |
(412,848 |
) |
$ |
(663,943 |
) |
$ |
(2,410,271 |
) |
$ |
(556,476 |
) |
|||
Participating securities' share in earnings |
|
(139 |
) |
|
(349 |
) |
|
(946 |
) |
|
(1,644 |
) |
|||
Net loss, less participating securities' share in earnings | $ |
(412,987 |
) |
$ |
(664,292 |
) |
$ |
(2,411,217 |
) |
$ |
(558,120 |
) |
|||
Depreciation and amortization |
|
79,396 |
|
|
95,648 |
|
|
509,524 |
|
|
676,132 |
|
|||
(Gain) loss on sale of real estate |
|
(3,497 |
) |
|
2,024 |
|
|
(478,693 |
) |
|
1,815 |
|
|||
Real estate impairment charges |
|
300,987 |
|
|
112,112 |
|
|
980,263 |
|
|
167,966 |
|
|||
Funds from operations | $ |
(36,101 |
) |
$ |
(454,508 |
) |
$ |
(1,400,123 |
) |
$ |
287,793 |
|
|||
Write-off of billed and unbilled rent and other |
|
(332 |
) |
|
499,335 |
|
|
2,514 |
|
|
649,911 |
|
|||
Other impairment charges, net |
|
85,986 |
|
|
171,507 |
|
|
1,255,929 |
|
|
208,941 |
|
|||
Litigation and other |
|
4,801 |
|
|
2,899 |
|
|
51,308 |
|
|
15,886 |
|
|||
Share-based compensation adjustments |
|
- |
|
|
(6,571 |
) |
|
- |
|
|
(9,691 |
) |
|||
Non-cash fair value adjustments |
|
52,194 |
|
|
8,405 |
|
|
563,666 |
|
|
(34,157 |
) |
|||
Tax rate changes and other |
|
523 |
|
|
(2,797 |
) |
|
5,119 |
|
|
(167,332 |
) |
|||
Debt refinancing and unutilized financing costs (benefit) |
|
615 |
|
|
(239 |
) |
|
4,292 |
|
|
(285 |
) |
|||
Normalized funds from operations | $ |
107,686 |
|
$ |
218,031 |
|
$ |
482,705 |
|
$ |
951,066 |
|
|||
Certain non-cash and related recovery information: | |||||||||||||||
Share-based compensation | $ |
2,321 |
|
$ |
10,102 |
|
$ |
32,902 |
|
$ |
42,941 |
|
|||
Debt costs amortization | $ |
5,292 |
|
$ |
4,933 |
|
$ |
20,061 |
|
$ |
20,273 |
|
|||
Non-cash rent and interest revenue (A) | $ |
- |
|
$ |
(57,920 |
) |
$ |
- |
|
$ |
(239,599 |
) |
|||
Cash recoveries of non-cash rent and interest revenue (B) | $ |
542 |
|
$ |
2,364 |
|
$ |
7,382 |
|
$ |
38,451 |
|
|||
Straight-line rent revenue from operating and finance leases | $ |
(48,627 |
) |
$ |
(63,282 |
) |
$ |
(178,022 |
) |
$ |
(247,699 |
) |
|||
Per diluted share data: | |||||||||||||||
Net loss, less participating securities' share in earnings | $ |
(0.69 |
) |
$ |
(1.11 |
) |
$ |
(4.02 |
) |
$ |
(0.93 |
) |
|||
Depreciation and amortization |
|
0.14 |
|
|
0.16 |
|
|
0.86 |
|
|
1.13 |
|
|||
(Gain) loss on sale of real estate |
|
(0.01 |
) |
|
- |
|
|
(0.80 |
) |
|
- |
|
|||
Real estate impairment charges |
|
0.50 |
|
|
0.19 |
|
|
1.63 |
|
|
0.28 |
|
|||
Funds from operations | $ |
(0.06 |
) |
$ |
(0.76 |
) |
$ |
(2.33 |
) |
$ |
0.48 |
|
|||
Write-off of billed and unbilled rent and other |
|
- |
|
|
0.83 |
|
|
- |
|
|
1.09 |
|
|||
Other impairment charges, net |
|
0.14 |
|
|
0.29 |
|
|
2.08 |
|
|
0.35 |
|
|||
Litigation and other |
|
0.01 |
|
|
- |
|
|
0.09 |
|
|
0.03 |
|
|||
Share-based compensation adjustments |
|
- |
|
|
(0.01 |
) |
|
- |
|
|
(0.02 |
) |
|||
Non-cash fair value adjustments |
|
0.09 |
|
|
0.01 |
|
|
0.94 |
|
|
(0.06 |
) |
|||
Tax rate changes and other |
|
- |
|
|
- |
|
|
0.01 |
|
|
(0.28 |
) |
|||
Debt refinancing and unutilized financing costs (benefit) |
|
- |
|
|
- |
|
|
0.01 |
|
|
- |
|
|||
Normalized funds from operations | $ |
0.18 |
|
$ |
0.36 |
|
$ |
0.80 |
|
$ |
1.59 |
|
|||
Certain non-cash and related recovery information: | |||||||||||||||
Share-based compensation | $ |
- |
|
$ |
0.02 |
|
$ |
0.05 |
|
$ |
0.07 |
|
|||
Debt costs amortization | $ |
0.01 |
|
$ |
0.01 |
|
$ |
0.03 |
|
$ |
0.03 |
|
|||
Non-cash rent and interest revenue (A) | $ |
- |
|
$ |
(0.10 |
) |
$ |
- |
|
$ |
(0.40 |
) |
|||
Cash recoveries of non-cash rent and interest revenue (B) | $ |
- |
|
$ |
- |
|
$ |
0.01 |
|
$ |
0.06 |
|
|||
Straight-line rent revenue from operating and finance leases | $ |
(0.08 |
) |
$ |
(0.11 |
) |
$ |
(0.30 |
) |
$ |
(0.41 |
) |
Notes:
Investors and analysts following the real estate industry utilize funds from operations ("FFO") as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or Nareit, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization, including amortization related to in-place lease intangibles, and after adjustments for unconsolidated partnerships and joint ventures.
In addition to presenting FFO in accordance with the Nareit definition, we disclose normalized FFO, which adjusts FFO for items that relate to unanticipated or non-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts. We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs (if any not paid by our tenants) to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our results of operations or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity.
Certain line items above (such as depreciation and amortization) include our share of such income/expense from unconsolidated joint ventures. These amounts are included with all activity of our equity interests in the "Earnings (loss) from equity interests" line on the consolidated statements of income.
(A) Includes revenue accrued during the period but not received in cash, such as deferred rent, payment-in-kind ("PIK") interest or other accruals.
(B) Includes cash received to satisfy previously accrued non-cash revenue, such as the cash receipt of previously deferred rent or PIK interest.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226322304/en/
Drew Babin, CFA, CMA
Head of Financial Strategy and Investor Relations
Medical Properties Trust, Inc.
(646) 884-9809
dbabin@medicalpropertiestrust.com
Source: Medical Properties Trust, Inc.
FAQ
What is the impact of MPW's $2.5 billion senior secured notes offering on its debt structure?
How did Medical Properties Trust (MPW) perform financially in Q4 2024?
What is the current size and composition of MPW's property portfolio?
How much is Medical Properties Trust's quarterly dividend for 2024?